New genotype classification and molecular characterization of canine and feline paroviruses

Hee-Chun Chung 1,†, Sung-Jae Kim 1,†, Van Giap Nguyen 2,†, Sook Shin 3, Jae Young Kim 4, Suk-Kyung Lim 5, Yong Ho Park 3,*, BongKyun Park 1,*

1Department of Veterinary Medicine Virology Lab, College of Veterinary Medicine and Research Institute for Veterinary Science, Seoul National University, Seoul 08826, Korea
2Department of Veterinary Microbiology and Infectious Diseases, Faculty of Veterinary Medicine, Vietnam National University of Agriculture, Hanoi 100000, Vietnam
3Department of Veterinary Microbiology, College of Veterinary Medicine and Research Institute for Veterinary Science, Seoul National University, Seoul 08826, Korea
4Tae Neung Animal Hospital, Seoul 02033, Korea
5Bacterial Disease Division, Animal and Plant Quarantine Agency, Gimcheon 39660, Korea

ABSTRACT

Background: Canine parvovirus (CPV) and feline panleukopenia (FPV) cause severe intestinal disease and leukopenia.

Objectives: In Korea, there have been a few studies on Korean FPV and CPV-2 strains. We attempted to investigate several genetic properties of FPV and CPV-2.

Methods: Several FPV and CPV sequences from around the world were analyzed by Bayesian phylo-geographical analysis.

Results: The paroviruses strains were newly classified into FPV, CPV 2-I, CPV 2-II, and CPV 2-III genotypes. In the strains isolated in this study, Gigucheon, Rara and Jun belong to the FPV, while Rachi strain belong to CPV 2-III. With respect to CPV type 2, the new genotypes are inconsistent with the previous genotype classifications (CPV-2a, -2b, and -2c). The root of CPV-I strains were inferred to be originated from a USA strain, while the CPV-II and III were derived from Italy strains that originated in the USA. Based on VP2 protein analysis, CPV 2-I included CPV-2a-like isolates only, as differentiated by the change in residue S297A/N. Almost CPV-2a isolates were classified into CPV 2-III, and a large portion of CPV-2c isolates was classified into CPV 2-II. Two residue substitutions F267Y and Y324I of the VP2 protein were characterized in the isolates of CPV 2-III only.

Conclusions: We provided an updated insight on FPV and CPV-2 genotypes by molecular-based and our findings demonstrate the genetic characterization according to the new genotypes.

Keywords: Canine parvovirus; feline paroviruses; classification; genotype

INTRODUCTION

Canine parvovirus (CPV) and feline panleukopenia virus (FPV) are members of the genus Protovirus [1], belonging to the family Parvoviridae, and are small, non-enveloped DNA viruses with a single-stranded linear genome of approximately 5.2 kb [1,2]. The CPV and FPV cause severe intestinal disease and leukopenia in canine and feline [3,4].
Canine parvovirus represents the cross-species viral transmission between felines and canines. Parvovirus CPV type 2 (CPV-2) emerged during the 1970s and rapidly spread worldwide [5,6]. Although there is still some controversy surrounding the origin of CPV-2, most researchers and clinicians accept that CPV-2 is derived from FPV of domestic cats [3]. Subsequently, two new antigenic types of CPV-2, type 2a (CPV-2a) and type 2b (CPV-2b), emerged and have virtually replaced the original CPV-2 strain worldwide [7]. Another antigenic type, CPV type 2c (CPV-2c) emerged in the 2000s and spread globally [4]. The novel antigenic categories appeared consecutively after the initial discovery of CPV-2 as a variant of FPV, and the genomes of the carnivore parvoviruses are 98% homologous to each other [6] with few nonsynonymous and synonymous changes of nucleotides [8]. Extensive phylogenetic studies on CPV-2 and FPV isolates reveal that there are 2 distinct clusters represented by FPV type from cats (FPV), raccoons, and mink, and by CPV type from dogs and raccoon dogs [3,7-9].

Two open reading frames exist in the parvovirus genome. One codes for non-structural proteins (NS1 and NS2) and has low nucleotide substitution, and the other codes for structural viral proteins (VP1 and VP2) [9]. The 2 structural viral proteins are splice variants and are identical in sequence except for a 143 amino acid (aa) long N-terminal stretch that is unique to VP1. The VP2 is the major capsid protein that comprises about 90% of the entire viral capsid [10]. This capsid is a determinant of host range as a main target for neutralizing antibodies against parvovirus [9]. So far, most studies have investigated on the evolution of the VP2 gene instead of studies that are focused on VP1.

Although DNA viruses have a lower mutation rate as compared to RNA viruses, the genomic substitution rate for both CPV and FPV is comparable to that observed for RNA viruses rather than other types of DNA viruses [11]. Although it can be postulated that consecutive genetic evolution has occurred, there are scarce data on genetic analysis and the topology of FPV and CPV worldwide. Moreover, no comprehensive genetic analysis on Korean CPV and FPV isolates has been carried out, although there are a few studies that attempted to do so [12-16]. We performed an extensive genetic analysis using the Bayesian method on over 200 previously published CPV and FPV sequences including recent Korean CPV and FPV isolates. From our novel study perspective, we suggest a new genetic classification for CPV (CPV 2-I, -II and -III) as an alternate to the conventional genotype classification (CPV-2a, -2b, and -2c) as proposed by other genetic analyses.

**MATERIALS AND METHODS**

**Sample collection and polymerase chain reaction (PCR)-based detection of FPV and CPV-2**

For detection of FPV and CPV-2, rectal swab samples were collected from cats and dogs showing viral clinical symptoms (less than 6 months) that were hospitalized at three different animal clinics (Rara, Gigucheon, and Rachi) in Seoul and one animal clinic (Jun) in Suwon from June 2017 to October 2017 (Table 1). The collected four samples were suspended in 1 mL of 0.1M phosphate-buffered saline (PBS) at pH 7.4 and centrifuged at 2,500 g for 15 min at 4°C. The supernatant from each sample was collected and used for PCR amplification.

DNA extraction was performed using an RNA/DNA Extraction kit (Invitrogen, USA) according to the manufacturer's instructions and the extracted samples were stored at −20°C.
All rectal swab samples were tested using the primer sets for FPV, CPV-2, and other viral pathogens listed in Table 2. The PCR thermal profile was as follows: initial denaturation at 94°C for 5 min, then 35 cycles of 94°C for 30 sec, 56°C for 30 sec, 72°C for 45 sec, and a final extension phase at 72°C for 7 min.

### Isolation of FPV and CPV-2

A monolayer of CRFK cells (ATCC® CCL-94™) was grown overnight to approximately 80–100% confluence in a 25-cm² cell culture flask. The cells were washed twice with 1× PBS prior to inoculation with a 10% suspension of the samples (Rara, Gigucheon, Rachi, and Jun), which were previously diluted in 500 mL PBS and filtered through a 0.02 µm filter. After two hours incubation at 37°C and 5% CO₂, 4.5 mL of cell growth media (Dulbecco’s minimum essential medium) supplemented with trypsin (10 µg/mL) and antibiotic-antimycotic solution (5 µL/mL) were added at a ratio of 1:10. After inoculation, the cells were monitored daily for

---

### Table 1. Detailed information of the parvovirus-isolated samples in this study

| GenBank Strain | Site        |  Sampling date | Host | Age | Vaccine | Sample type | Clinical presentation |
|----------------|-------------|----------------|------|-----|---------|--------------|-----------------------|
| MN400981 Rachi | Seoul       | 06-June-2017   | Canine | 1 | Yes (DHPP) | Rectal swab | Hemorrhagic diarrhea |
| MN400978 Gigucheon | Seoul   | 16-July-2017   | Feline | 1 | Yes (RCP) | Rectal swab | Panleukopenia (depression, loss of appetite, high fever, vomiting, severe diarrhea) |
| MN400980 Rara | Seoul       | 18-August-2017 | Feline | 1 | Yes (RCP) | Rectal swab | Panleukopenia (depression, loss of appetite, high fever, vomiting, severe diarrhea) |
| MN400979 Jun | Gyeonggi; Suwon | 10-October-2017 | Feline | 1 | Yes (RCP) | Rectal swab | Panleukopenia (depression, loss of appetite, high fever, vomiting, severe diarrhea) |

DHPP, dog annual core vaccine of Distemper, Hepatitis, Parainfluenza, and Parvovirus; RCP, cat annual core vaccine of Rhinotracheitis, Calicivirus, and Panleukopenia.

### Table 2. List of primers used in this study

| Primer names | Detection method | Sequence (5'-3') | Location (nt) | Purpose | Size (bp) | References |
|--------------|------------------|------------------|---------------|---------|-----------|------------|
| CPV-F1       | PCR              | AGATAGTAAATATCTGATTGCAA | 531-1250      | Detection | 719       | [28]       |
| CPV-R2       |                  | TTTTGAATCCAATCTCCTTGTGGTGTA | -            | Detection | 504       | [29]       |
| CaKV-F       | RT-PCR           | CCCTGGAACACCCAAAGCGCTCACTGGTTGCCATGATT | -            | Detection | 669       | [29]       |
| CDV-F        | RT-PCR           | AACTTCCTGGACATCGTTGATTACGGTCACTGG | -            | Detection | 721       | [30]       |
| Herpesvirus type 1F | PCR | CTATGTCTCTATATGATTGAGACCTTGTGGATATGCTTT | 359-665       | Detection | 307       | [30]       |
| Herpesvirus type 1R | PCR | ATGATGGTGGAAGAGCCTCTGGTGCTATGGCC | 1-1253a       | Genome sequencing | 1,253 | In this study |
| CPV-1F       | PCR              | CAACAGTATGATGAACTATCCCAAGCTCTCGTCTGATGCG | 1-1253a       | Genome sequencing | 1,253 | In this study |
| CPV-2F       | PCR              | GACAGGTTGTAAAGAAGGTCAATGATGTTGTTGCAGTCTTC | 1163-2445     | Genome sequencing | 1,283 | In this study |
| CPV-2R       | PCR              | TCTGCGTTCCATATGTTGCTTGCACTCGTCG | 2345-3644     | Genome sequencing | 1,300 | In this study |
| CPV-3F       | PCR              | GAGCTAAAGGACCTGTCTTTCTGCATCGTCG | 3549-4269     | Genome sequencing | 721 | In this study |
| CPV-3R       | PCR              | TTAGATGAATATGATCTGGTAATGCTCTTCGTCG | 1-1419b       | Genome sequencing | 1,419 | In this study |
| CPV-4F       | PCR              | TTAGATGAATATGATCTGGTAATGCTCTTCGTCG | 1372-2827     | Genome sequencing | 1,456 | In this study |
| CPV-4R       | PCR              | CACATGCTATAGGCTGACACAA | 1372-2827     | Genome sequencing | 1,456 | In this study |
| CPV-5F       | PCR              | GAACTGGCCTGCTGCTGGCTGCTG | 2738-4240     | Genome sequencing | 1,503 | In this study |
| CPV-5R       | PCR              | GCATGCTATAGGCTGACACAA | 4161-4837     | Genome sequencing | 677 | In this study |
| FPV-1F       | PCR              | CTTAGACCCACAGCTGACACAA | 1-1419b       | Genome sequencing | 1,419 | In this study |
| FPV-1R       | PCR              | CACATGCTATAGGCTGACACAA | 1-1419b       | Genome sequencing | 1,419 | In this study |
| FPV-2F       | PCR              | GAATGCACGGATGGAATGTTCCGACAGCAGGATGGAATG | 1372-2827     | Genome sequencing | 1,456 | In this study |
| FPV-2R       | PCR              | CTGGATACGGTGGTACGACAGGACAC | 2738-4240     | Genome sequencing | 1,503 | In this study |
| FPV-3F       | PCR              | AAAAGCCGCGTGGACGGACAG | 4161-4837     | Genome sequencing | 677 | In this study |
| FPV-3R       | PCR              | GCATGCTATAGGCTGACACAA | 4161-4837     | Genome sequencing | 677 | In this study |

CPV, canine parvovirus; CDV, canine distemper virus; CaKoV, canine kobuvirus; PCR, polymerase chain reaction; RT-PCR, reverse transcription polymerase chain reaction.

*aSite location, reference, GenBank accession number KR002799; bSite location, reference, GenBank accession number MH559110.
cytopathic effects (CPEs). After 4–5 days observation for CPE, cells were harvested to confirm the presence of each virus type by reverse transcription (RT)-PCR. Serial passages of the Rara, Gigucheon, Rachi, and Jun isolates of FPV and CPV-2, were continued at 37°C in 5% CO₂ atmosphere to passage number 13.

**Immunofluorescence of assay of CRFK cells infected with FPV and CPV-2**
An immunofluorescence assay was performed for the 4 isolated strains (Rachi, Gigucheon, Rara, and Jun) with a negative control and positive control against canine parvovirus live vaccine (NeoPar, NeoTech) to confirm FPV or CPV-2 infection from passage level 13 in CRFK cells. After 1 day of fixation based on alcohols 100% with incubation −20°C. Approximately 300 µL of monoclonal primary antibody specific for parvovirus (CPV1-2A1) from Abcam Ltd. (cat No. ab140431), diluted 1:100, was applied to cells, and cells were then transferred to a 37°C incubator for 1 h. Afterwards, the primary antibody was rinsed and cells were incubated with the secondary antibody goat anti-mouse IgG H&L Alexa Fluor® 488 (cat No. ab150113) for 1 h.

**Complete genome sequencing of FPV and CPV-2**
For genetic characterization, the four isolates recovered in this study (Rachi, Rara, Gigucheon, and Jun) were completely sequenced by the primer walking method. Four pairs of overlapping primers were utilized for sequencing the Rara, Gigucheon, and Jun strains (FPV 1F to 4R), and for the Rachi strain (CPV 1F to 4R), as shown in Table 2. Specific PCR products were purified by the gel extraction method and further processed for TA cloning and transformation [17]. The full-length genomes of Gigucheon, Jun, Rara, and Rachi strains were registered in GenBank (accession numbers MN400978 to MN400981).

**Bayesian phylogenetic analyses**
For the genetic analyses, we downloaded different datasets from GenBank of 200 complete genome sequences, and 200 NS1, 200 VP1, and 275 VP2 protein-coding genes. These sequences originated from Asia (China, Thailand, Mongolia, India, Korea, and Japan), America (Uruguay, Argentina, USA, and Brazil), and Europe (Italy, Albania, New Zealand, United Kingdom, Germany, France, and Canada), that were sampled from 1964–2018.

This dataset was chosen for the Bayesian coalescent-based Markov chain Monte Carlo (MCMC) analysis. All analyses were performed using BEAST package v1.8.4 under the following assumptions: (i) HKY+G4 nucleotide substitution model in codon-based SRD06 [18], (ii) a constant population size for the coalescent prior, and (iii) the three molecular clock models of uncorrelated relaxed clock model (UCLD). The phylogenetic trees were summarized with TreeAnnotator v1.7.2 to determine the maximum clade credibility (MCC) tree, which was depicted using FigTree v1.4.3.

**Antigenic analysis on a B cell epitope of Korean FPV and CPV-2 strains**
B cell epitopes on the VP2 protein of FPV and CPV-2 strains epitope were already determined site of the 1 to 23 aa [19]. Also, the same position was predicted as the B cell epitope by BepiPred-2.0 version in this study [20]. The Jameson–Wolf antigenic index implemented using Lasergene Protean software (DNASTAR, Inc., USA) was used to predict whether aa substitutions would affect the antigenic properties of neutralizing epitopes. The antigenic index was calculated for each aa site and plotted using Microsoft Excel 2017 (Microsoft, USA).
RESULTS

Feline and Canine parvovirus detection and isolation

In the samples collected from the four clinics (Rachi, Rara, Jun, and Gigucheon), FPV or CPV-2 parvovirus was detected by CPV-specific PCR target band size of 719 bp. Other pathogens (canine kobuvirus, canine herpesvirus, and canine distemper virus) were not detected. As shown in Table 1, the four strains (Rachi, Rara, Jun, and Gigucheon) were isolated successfully from the CRFK cell line. For the Rachi strain, cytopathic effects on the cells were observed earlier (passage 1, 48 h after inoculation) than for the other three strains (passage 2, 72 h after inoculation). Among the isolated strains, the highest infective titers were for the Rachi isolate, increasing the median tissue culture infectious dose (TCID50) from $10^{4.5}$ at passage 3 to a TCID50 of $10^{7.5}$ at passage 13 (Table 3). Beginning at passage level 10, the four strains showed the strongest CPE with cell rounding and detachment (not shown). To confirm the viral isolation, an indirect immunofluorescence assay was performed to identify CRFK cells (from passage 10) infected by FPV and CPV-2. All four strains in CRFK cells showed positive nuclear green fluorescence at 24 h post-inoculation (Fig. 1).

Table 3. Titration of parvoviruses isolates from passage 1 to passage 13 in CRFK cells

| Strains       | Passages |
|---------------|----------|
|               | 1        | 2        | 3        | 4        | 5        | 6        | 7        | 8        | 9        | 10       | 11       | 12       | 13       |
|               | CPE Titer | CPE Titer | CPE Titer | CPE Titer | CPE Titer | CPE Titer | CPE Titer | CPE Titer | CPE Titer | CPE Titer | CPE Titer | CPE Titer | CPE Titer |
| Rachi         | +  N      | +  N      | ++  4.5  | +++  N    | +++  5.5  | +++  N    | +++  6.0  | +++  N    | +++  6.5  | +++  N    | +++  7.0  | +++  7.5  |
| Gigucheon     | -  N      | -  N      | +  2.0   | ++  N     | ++  2.5   | ++  N     | ++  4.0   | ++  N     | ++  4.5   | ++  N     | ++  5.0   | ++  6.0   |
| Rara          | -  N      | +  N      | +  3.5   | ++  N     | +++  4.0  | +++  N    | +++  4.5  | +++  N    | +++  5.0  | +++  N    | +++  6.0  | +++  6.3  |
| Jun           | -  N      | +  N      | +  3.0   | ++  N     | ++  4.5   | +++  N    | +++  6.0  | +++  N    | +++  6.5  | +++  N    | +++  7.0  | +++  7.5  |

CPE, cytopathic effect; N, not determined
+ small, ++ medium, +++ strong; $^b$Infection titer: log$_{10}$ TCID$_{50}$/mL.

Fig. 1. Results of IFA based on fluorescence microscopy. Specific IFA staining of CRFK cells infected by CPV (Rachi) and FPV (Gigucheon, Rara, and Jun) isolates at passage level 10. The specific Alexa Fluor® 488 (Green) images (arrow marked; gray color) were taken 24 h post-inoculation. The white scale bar in the micrographs = 100 µm.
IFA, immunofluorescence assay; CPV, canine parvovirus.
Evolutionary rates of CPV-2 and FPV

The evolutionary rates of the genes CPV-2 and FPV were inferred from the UCLD molecular clocks. As shown in Table 4, the investigated complete genomes, NS1, VP1, and VP2 genes were estimated to be rapidly evolving on the order of $10^{-4}$ nucleotide substitutions/site/year. The magnitude of the differences between the highest and lowest geometric mean rates were approximately 2-fold, within the range of $3.92 \times 10^{-4}$ (NS2 gene) and $1.96 \times 10^{-4}$ (NS1 gene). Notably, the 95% highest posterior density evolutionary rates observed among the genes revealed that the NS2 gene was the most varied ($2.50 \times 10^{-4} - 5.44 \times 10^{-4}$).

Bayesian geographical phylogenetic analyses of FPV and CPV-2

Of the phylogenetic tree topology (Fig. 2A-D), among the four datasets the FPV and CPV-2 strains were consistently divided into three genotypes as CPV 2-I, 2-II and 2-III with a posterior probability of 85%–99%. Of the viruses circulating in South Korea in 2007 and in 2014–2018, the phylogenetic trees reconstructed from three datasets indicated that they were grouped within the FPV, CPV 2-I, and CPV 2-III genotypes (Fig. 2D in VP2 protein, highlighted in gray color). Of these, the Rara, Gigucheon, and Jun isolates were included in FPV clade and the isolate Rachi was included in the CPV 2-III clade.

Focusing on the VP2 protein (Fig. 2D) of branching pattern of CPV-2, the CPV 2-I genotype included only the isolates from the USA, China and Korea. The CPV 2-II genotype did not included the strains from Asian countries including China, Thailand and Korea. The CPV 2-III genotype included the isolates from most countries located in Asia, Europe, North and South America. Interestingly, USA strains were not included in the CPV-2 III genotype. According to branch cascade, it is inferred that CPV 2-I isolates diverged from an ancestral USA strain. The CPV 2-II and -III isolates were regarded as being more recently diverged from Italian isolates originated from an ancestral USA strain (Fig. 2A-D).

Variations at the neutralizing epitope in the VP2 of CPV and FPV Korean strains

Using the B cell epitope prediction program, this study predicted potential linear epitopes on the VP2 protein site of 1 to 23 aa. The aa variations in the B cell epitopes (Fig. 3) were observed between three Korean FPV field strains (Jun, Rara, and Gigucheon) and reference FPV and CPV-2 strains. To access the influence of aa substitutions, the Jameson–Wolf antigenic index of VP2 were analyzed. As shown in Fig. 3A (VP2 gene) with gray color highlights, the predicted epitope (1 to 23 aa) of the three Korean CPV and FPV strains (Jun, Rara, and Gigucheon) showed significant differences in antigenic index with the other Korean strains. For example, epitope regions in 3, 4, 11, 12, and 13 aa had a lower antigenic index than the other Korean FPV and CPV-2 strains in the comparison. The aa substitution of Rara (3Asp→3Glu, 6Val→6Phe, 9Asp→9Asn, 16Arg→16Lys, 19Arg→19Lys) and Gigucheon (6Val→6Phe, 9Asp→9Asn, 16Arg→16Lys, 19Arg→19Lys, 20Ala→20Pro) resulted in the alteration of the antigenic index due to aa substitutions.

Table 4. Estimated nucleotide substitution rates of complete genomes for each gene

| Gene    | No. of sequences used | The clock model | Mean rate | 95% HPD interval         |
|---------|-----------------------|-----------------|-----------|--------------------------|
| Complete| 200                   | UCLD            | $2.85 \times 10^{-4}$ | $2.23 \times 10^{-4}$ to $3.64 \times 10^{-4}$ |
| NS1     | 200                   | UCLD            | $1.96 \times 10^{-4}$ | $1.46 \times 10^{-4}$ to $2.56 \times 10^{-4}$ |
| NS2     | 200                   | UCLD            | $3.92 \times 10^{-4}$ | $2.50 \times 10^{-4}$ to $5.44 \times 10^{-4}$ |
| VP1     | 200                   | UCLD            | $2.47 \times 10^{-4}$ | $1.77 \times 10^{-4}$ to $3.33 \times 10^{-4}$ |
| VP2     | 277                   | UCLD            | $2.95 \times 10^{-4}$ | $2.32 \times 10^{-4}$ to $3.69 \times 10^{-4}$ |

UCLD, uncorrelated relaxed clock model; HPD, highest posterior density.

aUCLD with an underlying lognormal distribution. bThe geometric mean nucleotide substitution rate (substitutions/site/year).
Amino acid mutation analysis based on the VP2 protein

The results of aa analysis based on the VP2 protein are shown in Table 5. There were common residue substitutions between the FPV and CPV-2 isolates. The FPV isolates presented K-80, K-93, V-103, D-323, N-564, and A-568, but the CPV-2 isolates exhibited R-80, N-93, A-103, N-323, S-564, and G-568 at the same position except for only one isolate 9985-46 (Japan, 2017) depicted by K-93. Within the FPV isolates, three recent FPV isolates Gigucheon (Korea, 2017), Rara (Korea, 2017) and TN/FPV (India, 2018) had residue substitutions in the front region (residues 2 to 20) of the VP2 sequence as compared to other FPV isolates. The FPV
isolate Gigucheon (Korea, 2017), Rara (Korea, 2017) and TN/FPV (India, 2018) were noted as V6F/D9N/R16K/R19K/A20P, D3E/V6F/D9N/R16K/R19K, and A5P/V6F/Q7H/D9N/R16K/R19K in this region, respectively.

The CPV 2-I isolates were completely differentiated from each other by the change at residue 297 on the VP2 protein. The CPV 2-I isolates exhibited S-297 only, but the CPV 2-II and -III isolates presented A- or N-297 and A-297, respectively. Residue 297-309 (SEGATNFDGVE) forms the exposed surface of the capsid protein that neutralizing antibody binds to [21]. In this antigenic region, the CPV 2-I isolate CPV-13 (USA, 1981) and CPV-L (China, 2014) presented residue changes of A300G, D305Y and A300S, and D305Y respectively, as compared to the other CPV 2-I isolates. The CPV 2-II isolate Arg9 (Argentina, 2008), Arg50 (Argentina, 2008), Arg68 (Argentina 2010), Bra03/13 (Brazil, 2013), and Bra05/13 (Brazil, 2013) displayed a residue change of A300N as compared to other CPV 2-II isolates. In an intra-group comparison of CPV 2-III, the isolate Pome (Korea, 2007) and 9985-46 (Japan, 2017) had residue changes of G300D and G300V, respectively. The isolate RC14/BC (Canada, 2010), RC19/BC (Canada, 2016), and RC20/BC (Canada, 2016) presented respective residue changes of G300D, T301A, and Y305H. Two characterized residue substitutions appeared
Table 5. Amino acid mutations in VP2 protein of FPV and CPV isolates

| GenBank accession no | Strain name | Year | Mutations sites: amino acid residue | Genotype |
|----------------------|-------------|------|------------------------------------|----------|
| EU498680 | Purevax, Italy | 2008 | D A V Q D R R A K K V F S A T D D Y N N A | FPV |
| EU498681 | Felocell, Italy | 2008 | D A V Q D R R A K K V F S A T D D Y N N A | FPV |
| MN400979 | Jun, Korea | 2017 | D A V Q D R R A K K V F S A T D D Y N N A | FPV |
| MN400978 | Giguicheon, Korea | 2017 | D A V Q D R R A K K V F S A T D D Y N N A | FPV |
| MN400980 | Raro, Korea | 2017 | E A F Q N K K A K K V F S A T D D Y N N A | FPV |
| MHX5910 | FPV, India | 2018 | D P F H N K K A K K V F S A T D D Y N N A | FPV |
| EU65916 | CPV-5, USA | 1979 | D A V Q D R R A K K V F S A T D D Y N N A | CPV-2-I |
| EU65918 | CPV-13, USA | 1981 | D A V Q D R R A K K V F S A T D D Y N N A | CPV-2-I |
| FJ197846 | CPVint, Korea | 2007 | D A V Q D R R A K K V F S A T D D Y N N A | CPV-2-I |
| FJ197847 | CPVpf, Korea | 2007 | D A V Q D R R A K K V F S A T D D Y N N A | CPV-2-I |
| MG763189 | CPV-L, China | 2014 | D A V Q D R R A K K V F S A T D D Y N N A | CPV-2-I |
| MH213140 | 17Ra171, Korea | 2018 | D A V Q D R R A K K V F S A T D D Y N N A | CPV-2-I |
| AY742932 | CPV-193, USA | 1991 | D A V Q D R R A K K V F S A T D D Y N N A | CPV-2-II |
| AY742934 | CPV-447, Germany | 1995 | D A V Q D R R A K K V F S A T D D Y N N A | CPV-2-II |
| MF772241 | Arg9, Argentina | 2008 | D A V Q D R R A K K V F S A T D D Y N N A | CPV-2-II |
| MF77228 | 485-09, Italy | 2009 | D A V Q D R R A K K V F S A T D D Y N N A | CPV-2-II |
| KM457118 | UY190, Uruguay | 2009 | D A V Q D R R A K K V F S A T D D Y N N A | CPV-2-II |
| MF77229 | 368-12, Alibaba | 2012 | D A V Q D R R A K K V F S A T D D Y N N A | CPV-2-II |
| MF77228 | 8R40373, Brazil | 2013 | D A V Q D R R A K K V F S A T D D Y N N A | CPV-2-II |
| MK806279 | ZZSS/PA34478/18, Italy | 2018 | D A V Q D R R A K K V F S A T D D Y N N A | CPV-2-II |
| MH545963 | TN, CPV2a, India | 2018 | D A V Q D R R A K K V F S A T D D Y N N A | CPV-2-II |
| MN400981 | Rachi, Korea | 2017 | D A V Q D R R A K K V F S A T D D Y N N A | CPV-2-II |
| MH660905 | 5, Mongolia | 2017 | D A V Q D R R A K K V F S A T D D Y N N A | CPV-2-II |
| MH711894 | CU24, Thailand | 2016 | D A V Q D R R A K K V F S A T D D Y N N A | CPV-2-II |
| MF805789 | Canine/China/01/2016, China | 2016 | D A V Q D R R A K K V F S A T D D Y N N A | CPV-2-II |
| JQ268284 | CPV-L22, China | 2011 | D A V Q D R R A K K V F S A T D D Y N N A | CPV-2-II |
| KM457102 | UY243, Uruguay | 2010 | D A V Q D R R A K K V F S A T D D Y N N A | CPV-2-II |
| KY403998 | CPV-YH, China | 2008 | D A V Q D R R A K K V F S A T D D Y N N A | CPV-2-II |
| EU009204 | K026, Korea | 2007 | D A V Q D R R A K K V F S A T D D Y N N A | CPV-2-II |
| MH19333 | TR, Korea | 2018 | D A V Q D R R A K K V F S A T D D Y N N A | CPV-2-II |
| MG434740 | IZSSI/PA3213, Italy | 2017 | D A V Q D R R A K K V F S A T D D Y N N A | CPV-2-II |
| LC208182 | 9985-46, Japan | 2017 | D A V Q D R R A K K V F S A T D D Y N N A | CPV-2-II |
| MF069442 | CPV/RC14/BC, Canada | 2010 | D A V Q D R R A K K V F S A T D D Y N N A | CPV-2-II |
| EF599098 | Pome, Korea | 2007 | D A V Q D R R A K K V F S A T D D Y N N A | CPV-2-II |
| EU65919 | CPV-410, USA | 2000 | D A V Q D R R A K K V F S A T D D Y N N A | CPV-2-II |
| AY742935 | CPV-U6, Germany | 1995 | D A V Q D R R A K K V F S A T D D Y N N A | CPV-2-II |
| AY742933 | CPV-339, New Zealand | 1993 | D A V Q D R R A K K V F S A T D D Y N N A | CPV-2-II |
| FPV and CPV isolates in this study were indicated by italics (bold indicates this study). FPV, feline panleukopenia virus; CPV, canine parvovirus. |
only in the CPV 2-III isolates. Eighty-four CPV 2-III isolates from several countries (China, Korea, India, Mongolia, Thailand, Uruguay, and Italy) presented Y-267 and I-324, whereas other all FPV and CPV-2 isolates had F-267 and Y-324 at the same position.

**DISCUSSION**

The emergence of consecutive FPV and CPV variants are being reported worldwide [19,22,23]. The FPV and CPV which represent carnivore parvovirus have high nucleotide substitution rates as approximately 10^{-4} per site per year as compared to those observed in other DNA viruses [11]. Our results indicate similar rates of 1.96 to 3.92 × 10^{-4} according to complete genomes or to each non-structural or structural gene (NS1, VP1, and VP2; Table 4). Thus, it seems that this relatively high mutation rate allows for the continuous appearance of variants.

Until now, CPV-2 has been categorized as either type 2a, 2b, or 2c according to aa changes on the VP2 protein, since the virus was regarded as a variant of FPV first discovered in the 1970s, and this genetic classification method has been widely accepted [8,19,23,24]. However, previous phylogenetic analyses of the VP2 gene did not highly support the genetic classification, as low bootstrap values determined for each node diverged to other genotypes due to low genetic variability [4,13,14,16,22]. In contrast, the high informative results elicited from the Bayesian phylogenetic analysis in this study, showed clear classified into three different genotypes (designated as CPV 2-I, -II, and -III).

According to the conventional classification of CPV-2 divided into three variable types (CPV-2a, -2b, and -2c), the most relevant change was in residue 426 of the VP2 protein. Types CPV-2a, -2b, and -2c presented Asn (N), Asp (D) and Glu (E) at this position, respectively [19,23]. Our findings do not follow the previous genotyping pattern. The CPV 2-I clade included only CPV-2a isolates and CPV 2-II/III clades included each genetic isolate type (-2a, -2b and -2c; Fig. 2A-D).

The FPV isolates analyzed in this study formed one consolidated clade that were differentiated from the CPV-2 isolates. The residue changes in the VP protein differentiating FPV from CPV-2 were K- or Q80R, K90R, K93N, V103A, D323N, N564S, and A568G and these results were consistent with Ikeda et al. [25] except for residue 87, 232, and 297. The VP2 protein of FPV and CPV-2 encompasses major antigenic domains, and is regarded as a promising candidate immunogen with the capacity to induce neutralizing antibodies [19]. Residues A-91, V-92, N-93, and N-95 form the tip of a protruding area on the virus which also configures the antibody binding site in CPV-2 [21]. The change of K93N may contribute to an antigenic difference between FPV and CPV-2. There were no substitutions in this region throughout all CPV-2 isolates sequences analyzed. Interestingly, notable antigenic and genetic differences of VP2 protein were observed within residues 2 to 16 (SDGAVQPDGGQPAVR) which is one of four neutralizing antibody binding sites, although no other substitutions were observed in the other three binding sites, which are within residues 91-95 (AVNGN), 292-297 (NSLPQSS) and 297-309 (SEGATNFQGVE) [21]. Three recent FPV isolates derived from Korea (2017) and India (2018) showed the high variability in V6F/D9N/R16K (Gigucheon), D3E/V6F/D9N/R16K (Rara) and A5P/V6F/Q7H/D9N/R16K (TN/FPV) in this region, respectively. Further serological investigation is needed on these strains, because these changes may affect the overall antigenicity of FPV.

In the classification of CPV-2 genotype, CPV 2-I isolates were completely differentiated from each other by the change in residue 297 on the VP2 protein. The CPV 2-I isolates...
presented only S-297, whereas the CPV 2-II and -III isolates presented A- or N-297 and A-297, respectively. Only residue 297 is under positive selection pressure when analyzing viruses identified after 1990, but there was no evidence of positive selection sites during the 1980s [26]. As a result, most recent CPV-2a/2b/2c isolates present Ala (A) instead of Ser (S) at residue 297 position [23,26,27]. Thus, CPV 2-I isolates were considered as “old” CPV-2a strain-like virus from an evolutionary view.

Residues 292-297 (NSLPQSS) and 297-309 (SEGATNF DGVE) of the VP2 protein are antigenic sites that are exposed to neutralizing antibody [21]. Additional residue substitutions were found around the residue 297 when comparing CPV 2-I isolates with CPV 2-II and -III isolates. The CPV 2-I isolates presented A-300 and D-305 except for two isolates (CPV-13 and CPV-L), but almost all CPV 2-II and -III isolates presented G-300 and Y-305. Within CPV 2-II or -III isolates, some strains showed residue substitutions in this same region. Five isolates (Arg9, Arg50, Arg68, Bra03/13, and Bra05/13) had the residue change of A300N within CPV 2-II isolates. One Korean isolate (Pome), one Japanese isolate (9985-46) and three Canadian isolates (RC14/BC, RC19/BC, and RC20/BC) had residue changes of G300D, G300V and G300D/T301A/Y305H, respectively within CPV 2-III isolates. These substitutions in this region may be responsible for antigenic changes of CPV variants [27].

The numbers of CPV-2a, -2b, and -2c isolates constituting the CPV 2-II clade were one, 13, and 64, respectively and the corresponding numbers for CPV-2a, -2b, and -2c isolates forming the CPV 2-III clade were 94, 20, and 27. It is noteworthy that almost all CPV-2a isolates analyzed were classified into the CPV 2-III clade and a large portion of CPV-2c isolates analyzed was classified into the CPV 2-II clade. Two residue substitutions of the VP2 protein were characterized only in the isolates of CPV 2-III, although these changes were not consistently presented across the isolates of CPV 2-III. The changes of F267Y and Y324I were observed in many CPV 2-III isolates (84 out of 141) and these changes appeared with either residue but were mostly observed together. The simultaneous change of F267Y and Y324I was first observed in the Chinese strain CPV-YH isolated in 2008, and afterwards appeared extensively throughout the isolates recovered from several countries including China, Korea, India, Mongolia, Thailand, Uruguay and Italy. It is presumed that these substitutions act as a positive selection through CPV evolution within CPV 2-III isolates. Therefore, extensive and long-term investigation is required to validate this assumption. Residues 267 to 498 in the VP2 protein form a GH loop located between the βG and βH strands and this region has greatest variability in the parvovirus genome due to its exposure on the capsid surface [4]. Antigenic variability of CPV may be induced by residue substitutions of VP2 protein such as F267Y and Y324I.

The present study performed extensive genetic and phylogenetic analysis on FPV and CPV-2 isolates from Korea and other countries by Bayesian method. In the genetic analysis of VP2 protein, these isolates were classified into FPV and three CPV genotypes (CPV 2-I, -II and -III). The recent FPV isolates Gigucheon (Korea, 2017), Rara (Korea, 2017) and TN/FPV (India, 2018) showed high variability of the antigenic site. The CPV 2-I included only CPV-2a-like isolates under the old classification and were differentiated by the change of residue S297A or N. Almost all CPV-2a isolates were classified into CPV 2-III and the large portion of CPV-2c was classified into CPV 2-II. The residue changes of F267Y and Y324I were further characterized in CPV 2-III isolates. Residue changes of F267Y and Y324I were observed in many CPV 2-III isolates recovered after 2008 from several countries (China, Korea, India, Mongolia, Thailand, Uruguay, and Italy). Such substitutions are presumed to act as a
positive selection in the evolution of CPV, so additional investigation is required to verify this assumption. Residue substitutions within the exposed surface of capsid protein may lead to antigenic changes in CPV. To counteract the emergence of new CPV variants, continued surveillance of viruses and possibly new vaccines may be required.

ACKNOWLEDGMENTS

The authors would like to thank Jung Ah Kim and Eun Ok Kim for excellent technical assistance in CPVs antigen detection.

REFERENCES

1. Kelly WR. An enteric disease of dogs resembling feline panleucopaenia. Aust Vet J. 1978;54(12):593-593.
2. Shackelton LA, Hoelzer K, Parrish CR, Holmes EC. Comparative analysis reveals frequent recombination in the parvoviruses. J Gen Virol. 2007;88(Pt 12):3294-3301.
3. Appel MJ, Cooper BJ, Greisen H, Scott F, Carmichael LE. Canine viral enteritis. I. Status report on corona- and parvo-like viral enteritides. Cornell Vet. 1979;69(3):123-133.
4. Decaro N, Desario C, Parisi A, Martella V, Lorusso A, Miccolupo A, Mari V, Colaianni ML, Cavalli A, Di Trani L, Buonavoglia C. Genetic analysis of canine parvovirus type 2c. Virology. 2009;385(1):5-10.
5. Barker IK, Povey RC, Voigt DR. Response of mink, skunk, red fox and raccoon to inoculation with mink virus enteritis, feline panleukopenia and canine parvovirus and prevalence of antibody to parvovirus in wild carnivores in Ontario. Can J Comp Med 1983;47(2):188-197.
6. Parrish CR, Emergence, natural history, and variation of canine, mink, and feline parvoviruses. Adv Virus Res. 1990;38:403-450.
7. Parrish CR, O'Connell PH, Evermann JF, Carmichael LE. Natural variation of canine parvovirus. Science. 1985;230(4729):1046-1048.
8. Kariatsumari T, Horiuchi M, Hama E, Ishigurio N, Shinagawa M. Construction and nucleotide sequence analysis of an infectious DNA clone of the autonomous parvovirus, mink enteritis virus. J Gen Virol. 1991;72(Pt 4):867-875.
9. Parrish CR, Aquadro CF, Carmichael LE. Canine host range and a specific epitope map along with variant sequences in the capsid protein gene of canine parvovirus and related feline, mink, and raccoon parvoviruses. Virology. 1988;166(2):293-307.
10. Hueffer K, Parker JS, Weichert WS, Geisel RE, Sgro JY, Parrish CR. The natural host range shift and subsequent evolution of canine parvovirus resulted from virus-specific binding to the canine transferrin receptor. J Virol. 2003;77(3):1718-1726.
11. Shackelton LA, Parrish CR, Truyen U, Holmes EC. High rate of viral evolution associated with the emergence of carnivore parvovirus. Proc Natl Acad Sci U S A. 2005;102(2):379-384.
12. Jeoung SY, Ahn SJ, Kim D. Genetic analysis of VP2 gene of canine parvovirus isolates in Korea. J Vet Med Sci. 2008;70(7):719-722.
13. Kang BK, Song DS, Lee CS, Jung KI, Park SJ, Kim EM, Park BK. Prevalence and genetic characterization of canine parvoviruses in Korea. Virus Genes. 2008;36(1):127-133.
14. Moon HS, Lee SA, Lee SG, Choi R, Jeoung SY, Kim D, Hyun C. Comparison of the pathogenicity in three different Korean canine parvovirus 2 (CPV-2) isolates. Vet Microbiol. 2008;131(1-2):47-56. [PUBMED | CROSSREF]

15. Yoon SH, Jeong W, Kim HJ, An DI. Molecular insights into the phylogeny of canine parvovirus 2 (CPV-2) with emphasis on Korean isolates: a Bayesian approach. Arch Virol. 2009;154(8):1353-1360. [PUBMED | CROSSREF]

16. An DI, Jeong W, Jeoung HY, Yoon SH, Kim HJ, Park JY, Park BK. Phylogenetic analysis of feline panleukopenia virus (FPV) strains in Korean cats. Res Vet Sci. 2011;90(1):163-167. [PUBMED | CROSSREF]

17. Kim AR, Chung HC, Kim HK, Kim EO, Nguyen VG, Choi MG, Yang HI, Kim JA, Park BK. Characterization of a complete genome of a circular single-stranded DNA virus from porcine stools in Korea. Virus Genes. 2014;48(1):81-88. [PUBMED | CROSSREF]

18. Shapiro B, Rambaut A, Drummond AJ. Choosing appropriate substitution models for the phylogenetic analysis of protein-coding sequences. Mol Biol Evol. 2006;23(1):7-9. [PUBMED | CROSSREF]

19. López de Turiso JA, Cortés E, Ranz A, García J, Sanz A, Vela C, Casal JL. Fine mapping of canine parvovirus B cell epitopes. J Gen Virol. 1991;72(Pt 10):2445-2456. [PUBMED | CROSSREF]

20. Jespersen MC, Peters B, Nielsen M, Marcatili P. BepiPred-2.0: improving sequence-based B-cell epitope prediction using conformational epitopes. Nucleic Acids Res. 2017;45(W1):W24-W29. [PUBMED | CROSSREF]

21. Langeveld JP, Casal JJ, Vela C, Dalsgaard K, Smale SH, Puijk WC, Meloen RH. B-cell epitopes of canine parvovirus: distribution on the primary structure and exposure on the viral surface. J Virol. 1993;67(2):765-772. [PUBMED | CROSSREF]

22. Li X, Wu H, Wang L, Spibey N, Liu C, Ding H, Liu W, Liu Y, Tian K. Genetic characterization of paroviruses in domestic cats in Henan province, China. Transbound Emerg Dis. 2018;65(6):1429-1435. [PUBMED | CROSSREF]

23. Martella V, Decaro N, Buonavoglia C. Evolution of CPV-2 and implication for antigenic/genetic characterization. Virus Genes. 2006;33(1):11-13. [PUBMED | CROSSREF]

24. Ikeda Y, Mochizuki M, Naito R, Nakamura K, Miyazawa T, Mikami T, Takahashi E. Predominance of canine parvovirus (CPV) in unvaccinated cat populations and emergence of new antigenic types of CPVs in cats. Virology. 2000;278(1):13-19. [PUBMED | CROSSREF]

25. Ikeda Y, Nakamura K, Miyazawa T, Takahashi E, Mochizuki M. Feline host range of canine parvovirus: recent emergence of new antigenic types in cats. Emerg Infect Dis. 2002;8(4):341-346. [PUBMED | CROSSREF]

26. Pereira CA, Leal ES, Durigon EL. Selective regimen shift and demographic growth increase associated with the emergence of high-fitness variants of canine parvovirus. Infect Genet Evol. 2007;7(3):399-409. [PUBMED | CROSSREF]

27. Truyen U. Evolution of canine parvovirus—a need for new vaccines? Vet Microbiol. 2006;117(1):9-13. [PUBMED | CROSSREF]

28. Hirayama K, Kano R, Hosokawa-Kanai T, Tuchiya K, Tsuyama S, Nakamura Y, Sasaki Y, Hasegawa A. VP2 gene of a canine parovirus isolate from stool of a puppy. J Vet Med Sci. 2005;67(1):139-143. [PUBMED | CROSSREF]

29. Liu D, Liu F, Guo D, Hu X, Li Z, Li Z, Ma J, Liu C. One-step triplex PCR/RT-PCR to detect canine distemper virus, canine parvovirus and canine kobuvirus. J Vet Med Sci. 2019;81:1040-1042. [PUBMED | CROSSREF]

30. Liu MZ, Han XH, Yao LQ, Zhang WK, Liu B3, Chen ZL. Development and application of a simple recombinase polymerase amplification assay for rapid point-of-care detection of feline herpesvirus type 1. Arch Virol. 2019;164(1):195-200. [PUBMED | CROSSREF]